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The Barry report concludes that data generated using an in vitro challenge protocol indicates that OR/ Scrub®, a liquid handwash containing 1.0% triclosan, is susceptible to bacterial (primarily gram-negative species) contamination and lacks efficacy and safety for its use in the operating rooms, intensive care units, and other high-risk environments of hospitals. Additionally, information was quoted from the FDA's OTC Topical Antimicrobial Products Tentative Final Monograph (1978) to s u p p o r t the contention that triclosan is unsafe as a single antimicrobial active ingredient in surgical scrubs, health care personnel handwashes, and patient pre-operative preparations.
We agree that the Barry report developed data that indicate that there was a potential preservation problem with the original OR/Scrub® formulation. The report, however, strongly implies that triclosan is the reason for the documented contamination and could contribute to the proliferation of the contaminating organism. This conclusion is not supported by the evidence.
The authors themselves discuss other handwash products that contain other antimicrobial agents (chlorhexidine, iodophors, and hexachlorophene), in most cases used at higher concentrations than triclosan, documented to have been susceptible to bacterial contamination. The report also attempts to correlate the lack of gram-negative antimicrobial activity of hexachlorophene to triclosan based on chemical structure similarity. In fact, the two compounds are chemically different and in vitro testing documents significant difference in the antimicrobial activity between hexachlorophene and triclosan. 2 As far as the preservation problem is concerned, the manufacturer of OR/ Scrub® has reformulated the product to include a very effective preservative system that withstands the challenge of all the bacterial species mentioned in the Barry report and confirmed in the report's a d d e n d u m 3 (Oleson P, Friend M, unpublished data, 1984).
One should distinguish between antimicrobial agents used to prevent p r o d u c t d e t e r i o r a t i o n ("preservatives") and antimicrobial agents included for topical activity. The fact that a handwashing product has been found to be contaminated should not reflect adversely on the efficacy of an agent included as a skin antimicrobial. Triclosan itself is not susceptible to c o n t a m i n a t i o n . While h a n d w a s h products containing antimicrobials such as triclosan, chlorhexidine, povidone-iodine or hexachlorophene may, d e p e n d i n g on the particular product composition, be self-preserving, it should not be assumed by a supplier or user, that a skin antimicrobial ingredient will automatically also protect a product against m i c r o b i a l c o n t a m i n a t i o n . T h e finished product in its original container should be evaluated by the supplier for preservation capacity using an appropriate challenge test, for example USP or CTFA methods. Ciba-Geigy supports the promotion of triclosan as a topical antimicrobial agent with extensive data derived from in vivo test protocols such as glovejuice tests, basin tests, and artificial contamination of hands with bacteria (including gram-negative species) to more closely simulate actual in-use conditions 4 (Cox AR, unpublished data, 1981), (Schenkel A, Opferkuch M, Furia T, unpublished data, 1966).
Based on their data, Barry et al conclude that handwash products containing triclosan as a single active i n g r e d i e n t s h o u l d be considered unsafe and ineffective for use in operating rooms, intensive care wards, and areas where high-risk patients reside. To reinforce their conclusion, the FDA Antimicrobial Tentative Final Monograph (1978) is referenced. The reference, however, refers to an unsubstantiated hypothesis published in the original Tentative Final Monograph (1978) that postulates that prolonged use of triclosan-containing wash preparations on the skin could result in the overgrowth of gram-negative bacterial species. This theory has never been proven, either by scientific investigation or through practical experience and has been a continuing unresolved issue between the FDA and Ciba-Geigy. Ciba-Geigy disputes this theory based on data derived from controlled studies and in-use experience. Our investigations demonstrate that while triclosan is effective at reducing the bacterial level on skin, it does not eliminate all resident bacterial microflora on the skin, thus oneway pressure for the proliferation of a competing organism does not exist. Furthermore, many experts agree that normal dry skin is not a hospitable environment for the survival of gramnegative species. Long-term studies m e a s u r i n g t h e c o n s e q u e n c e s of exposure to triclosan, through frequent use of handwash products, failed to generate evidence that gramnegative bacteria would colonize and proliferate on the skin of the test subjects. 5 " 7 In May 1982, Ciba-Geigy received notification from the Division of OTC Drug Evaluation, Office of Drugs recommending that the status for use of triclosan in surgical scrubs, personnel health care handwashes, and patient p r e -o p e r a t i v e p r e p a r a t i o n s be changed from a not approved (Category 11) to a conditional approval (Category III) (W. Gilberston, personal communication, 1982) . Since receiving this notification, Ciba-Geigy has generated (and submitted to the FDA) additional data to support our position t h a t t r i c l o s a n is safe a n d efficacious for use in the clinical environment 4, 8 (Cox AR, unpublished data, 1981).
The antimicrobial effectiveness of a topically applied product is a function of the total formulation rather than a single ingredient. Based on the facts we have presented, it is clear that the conclusions of Barry et al are unsubstantiated.
IV Administration and Tracheostomy Care in the Home

To the Editor:
Please notify me if you have information concerning intravenous administration and tracheostomy care in the home. Our home health agency feels the frequency of changing IV tubing in the hospital might not be necessary in the home. Reimbursement sources are stressing resterilization and aseptic technique in the home for trach care.
We have not been able to locate d u r a b l e s u p p l i e s to w i t h s t a n d resterilization.
Wanda There have been no studies relating infection control practice to home health care. National organizations have not addressed appropriate infection control guidelines for this area. With this in mind, we must makejudg-
